The Study of KEDRAB® (Rabies Immune Globulin [Human]) Conducted in Children was the First and Only Pediatric Study for any HRIG Available in U.S. The Study Met its Primary Objective, Which Was to Confirm the Safety of KEDRAB in the Pediatric Population. Study Results Have Been Submitted to the U.S. FDA for Review and Potential […]
Click here for the recording of Kamada second quarter 2020 investor call. Second Quarter Revenues were $1 million, Compared to $35.3 million in 2019, First Half 2020 Revenues were $66.4 million, up 7% from 2019. Net Income for the Second Quarter and for the First Half of 2020 was $3.5 million and $8.7 million, Respectively, Compared […]
Study Participants are Hospitalized, Non-ventilated COVID-19 Patients with Pneumonia Encouraging Neutralization Activity Observed with Virus Neutralization Assay Pre-IND Meeting with U.S. FDA to be Conducted in Current Quarter, with U.S. Clinical Development Expected to Commence in Early 2021 Kamada Intends to Further Explore its IgG Product as a Potential Preventive Therapy for COVID-19 Disease in […]
Kamada Completed Manufacturing and Released the First Batch of its Plasma-Derived Immunoglobulin Product for Coronavirus Disease (COVID-19) and it is Available for Compassionate Use Treatment in Israel; Additional Production is On-Going Kamada Intends to Initiate a Phase 1/2 Clinical Study in Hospitalized COVID-19 Patients in Israel During the Third Quarter of 2020 Kamada and its […]
Total Revenues were $33.3 Million, an Increase of 24% Year-over-Year Net Income was $5.2 Million, an Increase of 6% Year-over-Year Company Reports Continued Progress of its Development Program of a Plasma-Derived Hyperimmune IgG Therapy for COVID-19; Product Availability for Clinical and Compassionate Use Treatment for COVID-19 patients in Israel is Expected by End of the […]
Rehovot, Israel, May 11, 2020 — Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31, 2020, prior to the open of the U.S. financial markets on Monday, May 18, 2020. Kamada management will host an investment community conference call on […]
Kamada is Responsible for Product Development, Manufacturing, Clinical Development, and Regulatory Submissions, as well as Distribution in Territories not under Kedrion’s Responsibility Kedrion is Responsible for the Collection and Supply of Plasma from Convalescent COVID-19 Patients, Support of Clinical Development and Distribution in the U.S., Europe, Australia, and S. Korea Rehovot, Israel and Castelvecchio Pascoli, […]
Rehovot, Israel, March 11, 2020 – Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial-stage plasma-derived biopharmaceutical company, today provided an update on progress related to its proprietary hyper-immunoglobulin (IgGs) product portfolio and platform technology. Kamada Plans to Utilize its Hyper-Immunoglobulin (IgG) Platform Technology to Develop an Anti-Corona (COVID-19) Immunoglobulin as a Potential Therapy for Severely […]
Total Revenues for Fiscal 2019 were $127.2 million, up 11% as Compared to 2018 Gross Profit for Fiscal 2019 was $49.7 Million, up 20% as Compared to 2018 Adjusted EBITDA for Fiscal 2019 was $28.5 Million, up 19% as Compared to 2018 As of December 31, 2019, the Company had Cash, Cash Equivalents, and Short-Term […]
Rehovot, Israel, February 5, 2020 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2019, prior to the open of the U.S. financial markets on Wednesday, February 12, 2020. Kamada management will host […]